title: Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
abstract: OBJECTIVE
  The prognosis for patients with glioblastoma multiforme (GBM) remains extremely poor despite recent treatment advances. There is an urgent need to develop novel therapies for this disease.
  
  
  METHODS
  We used the implantable GL261 murine glioma model to investigate the therapeutic potential of a vaccine consisting of intravenous injection of irradiated whole tumor cells pulsed with the immuno-adjuvant α-galactosylceramide (α-GalCer).
  
  
  RESULTS
  Vaccine treatment alone was highly effective in a prophylactic setting. In a more stringent therapeutic setting, administration of one dose of vaccine combined with depletion of regulatory T cells (Treg) resulted in 43% long-term survival and the disappearance of mass lesions detected by MRI. Mechanistically, the α-GalCer component was shown to act by stimulating "invariant" natural killer-like T cells (iNKT cells) in a CD1d-restricted manner, which in turn supported the development of a CD4(+) T-cell-mediated adaptive immune response. Pulsing α-GalCer onto tumor cells avoided the profound iNKT cell anergy induced by free α-GalCer. To investigate the potential for clinical application of this vaccine, the number and function of iNKT cells was assessed in patients with GBM and shown to be similar to age-matched healthy volunteers. Furthermore, irradiated GBM tumor cells pulsed with α-GalCer were able to stimulate iNKT cells and augment a T-cell response in vitro.
  
  
  CONCLUSIONS
  Injection of irradiated tumor cells loaded with α-GalCer is a simple procedure that could provide effective immunotherapy for patients with high-grade glioma.
authors.affiliation: Malaghan Institute of Medical Research, University of Otago, New Zealand. mhunn@malaghan.org.nz
authors.forename: Martin K
authors.initials: MK
authors.lastname: Hunn
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Farrand
authors.forename: Kate W R
authors.initials: KW
authors.lastname: Broadley
authors.forename: Robert
authors.initials: R
authors.lastname: Weinkove
authors.forename: Peter
authors.initials: P
authors.lastname: Ferguson
authors.forename: Rose J
authors.initials: RJ
authors.lastname: Miller
authors.forename: Cameron S
authors.initials: CS
authors.lastname: Field
authors.forename: Troels
authors.initials: T
authors.lastname: Petersen
authors.forename: Melanie J
authors.initials: MJ
authors.lastname: McConnell
authors.forename: Ian F
authors.initials: IF
authors.lastname: Hermans
mesh_terms: D000276:Adjuvants, Immunologic / Q000378:metabolism; D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005910:Glioma / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D006801:Humans; D008168:Lung / Q000276:immunology; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D051379:Mice; D018345:Mice, Knockout; D055611:Natural Killer T-Cells / Q000276:immunology* / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D047368:Tumor Burden / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines